Astrocytoma – pipeline review, h2 2012


Published on

2012 | Astrocytoma – Pipeline Review, H2 2012

Published in: Health & Medicine, Business
  • Be the first to comment

  • Be the first to like this

No Downloads
Total views
On SlideShare
From Embeds
Number of Embeds
Embeds 0
No embeds

No notes for slide

Astrocytoma – pipeline review, h2 2012

  1. 1. announces, The Latest market research report is available inits vast collection:Astrocytoma – Pipeline Review, H2 2012You can also request for sample page of above mention reports onsample@aarkstore.comSummaryGlobal Markets Direct’s, Astrocytoma - Pipeline Review, H2 2012, provides anoverview of the Astrocytoma therapeutic pipeline. This report provides informationon the therapeutic development for Astrocytoma, complete with latest updates, andspecial features on late-stage and discontinued projects. It also reviews key playersinvolved in the therapeutic development for Astrocytoma. Astrocytoma - PipelineReview, H2 2012 is built using data and information sourced from Global MarketsDirect’s proprietary databases, Company/University websites, SEC filings, investorpresentations and featured press releases from company/university sites andindustry-specific third party sources, put together by Global Markets Direct’s team.Note*: Certain sections in the report may be removed or altered based on theavailability and relevance of data for the indicated disease.Scope- A snapshot of the global therapeutic scenario for Astrocytoma.- A review of the Astrocytoma products under development by companies anduniversities/research institutes based on information derived from company andindustry-specific sources.- Coverage of products based on various stages of development ranging fromdiscovery till registration stages.
  2. 2. Table of contents:List of Tables 8List of Figures 11Introduction 12Global Markets Direct Report Coverage 12Astrocytoma Overview 13Therapeutics Development 14An Overview of Pipeline Products for Astrocytoma 14Astrocytoma Therapeutics under Development by Companies 16Astrocytoma Therapeutics under Investigation by Universities/Institutes 23Late Stage Products 31Comparative Analysis 31Mid Clinical Stage Products 32Comparative Analysis 32Early Clinical Stage Products 33Comparative Analysis 33Discovery and Pre-Clinical Stage Products 34Comparative Analysis 34Astrocytoma Therapeutics – Products under Development by Companies 35Astrocytoma Therapeutics – Products under Investigation by Universities/Institutes42Companies Involved in Astrocytoma Therapeutics Development 58F. Hoffmann-La Roche Ltd. 58Amgen Inc. 59Sanofi-Aventis 60AstraZeneca PLC 61Eli Lilly and Company 62Genentech, Inc. 63MedImmune LLC 64Merck & Co., Inc. 65Lentigen Corporation 66Sangamo BioSciences, Inc. 67Plexxikon Inc. 68
  3. 3. Celltrion, Inc. 69Ark Therapeutics Group plc 70Novartis AG 71Actelion Ltd 72Eisai Co., Ltd. 73Nippon Shinyaku Co., Ltd. 74Pfizer Inc. 75List of FiguresList of Tables are also include.For more related Reports Plz follow The link:Pipeline Review, H2 2012 Review, H22012&PubId=&pagenum=1Astrocytoma – Pipeline Review, H2 2012Autoimmune Disorders – Pipeline Review, H2 2012HIV / AIDS – Pipeline Review, H2 2012Contraceptives – Pipeline Review, H2 2012Metastatic Prostate Cancer – Pipeline Review, H2 2012Fungal Infections – Pipeline Review, H2 2012
  4. 4. Mycobacterium Infections – Pipeline Review, H2 2012Brain Cancer – Pipeline Review, H2 2012Metastatic Colorectal Cancer – Pipeline Review, H2 2012Orthomyxoviridae Infections – Pipeline Review, H2 2012Search More Reports Related to This Category :Pharmaceuticals and Healthcare andHealthcare&PubId=&pagenum=1For More details Plz do contact :Aarkstore EnterpriseLavanyaPhone:08149852585Email: